The word mellitus (/məˈlaɪtəs/ or /ˈmɛlɪtəs/) comes from the classical Latin word mellītus, meaning "mellite" (i.e. sweetened with honey; honey-sweet). The Latin word comes from mell-, which comes from mel, meaning "honey"; sweetness; pleasant thing, and the suffix -ītus, whose meaning is the same as that of the English suffix "-ite". It was Thomas Willis who in 1675 added "mellitus" to the word "diabetes" as a designation for the disease, when he noticed the urine of a diabetic had a sweet taste (glycosuria). This sweet taste had been noticed in urine by the ancient Greeks, Chinese, Egyptians, Indians, and Persians.
The classic oral glucose tolerance test measures blood glucose levels five times over a period of three hours. Some physicians simply get a baseline blood sample followed by a sample two hours after drinking the glucose solution. In a person without diabetes, the glucose levels rise and then fall quickly. In someone with diabetes, glucose levels rise higher than normal and fail to come back down as fast.
The guidelines, if widely accepted, would affect up to a quarter of Americans living with diabetes whose BMI is between 30 and 35. Worldwide, the effects would be even greater, since the majority of the 422 million people with diabetes have a BMI lower than 35. For people of Asian descent, the DSS-II agreed surgery could be considered for people down to 27.5 BMI, since many patients of Asian decent develop diabetes at a lower BMI.
Pain affects millions of people with diabetes. For most of these people, the pain is chronic, defined as pain persisting for more than six months, experienced almost every day, and of moderate to severe intensity, or that significantly interferes with daily activities. In some cases, a person’s pain is clearly related to complications of diabetes; in other cases, it is not. Regardless of the cause, however, studies show that chronic pain makes diabetes self-management much more difficult and often leads to higher blood glucose levels.
Body blasting was just one of the hundreds of classes, sessions, panels, talks, and silent dance parties at the inaugural Wellspring wellness festival. Last month some 2,000 mannequin-shaped people floated into Palm Springs, California, for what advertisements promised to be “a first-of-its-kind wellness festival, that will feature over 200 transformational workshops, treatments, and fitness across multiple categories.” The goal was to “provide seekers the tools to learn and take action in real time for a healthier mind in a relational platform.” (Relational platform was a new term to me, but people seemed less than pleased when I used the word conference.)
President Donald Trump’s decision to withdraw U.S. troops from Syria is controversial partly because of the possible consequences for the country’s Kurdish minority. “Among the biggest losers are likely to be the Kurdish troops that the United States has equipped and relied on to fight the Islamic State in Iraq and Syria,” The New York Times editorialized. “Turkey’s president, Recep Tayyip Erdogan, considers many of the Kurds to be terrorists bent on destroying his country. In recent days he has vowed to launch a new offensive against them in the Syrian border region.”
One participant in an online discussion on the Diabetes Self-Management blog wrote, “I noticed that when I was doing something like reading an interesting book, or walking and talking with a friend, I was not consciously feeling pain.” Another wrote, “I keep my mind busy with genealogy [family history] during the day. I play sudoku and crosswords at night until I can fall asleep.”
Poxel (PP:POXEL) is a French pharmaceutical company that recently received $30.1 million in post-IPO equity in 2016. The company has developed an orally active medication called Imeglimin, which targets all three organs and body systems that are affected by diabetes simultaneously: the pancreas, liver, and muscles. The drug is currently undergoing phase 3 clinical work in Japan, and will commence phase 3 trials in the European Union and the United States that will be completed by 2019. The company is also concurrently working on several other pharmaceutical agents in various stages of the development pipeline.
A good way to understand the many causes of chronic pain is by considering phantom limb pain. When people lose an arm or leg in an accident or surgery, about half of them will still feel that the limb is there. About half of those people develop serious pain in the phantom limb. Obviously, this isn’t due to physical injury going on in the moment. It’s a misunderstanding by the brain of the signals it is getting and not getting. The brain figures the signals add up to something seriously wrong, so it sends out an urgent pain message.
David Spero is author of Diabetes: Sugar-coated Crisis, (New Society, 2006) and The Art of Getting Well: Maximizing Health When You Have a Chronic Illness (Hunter House, 2002). He writes for Diabetes Self-Management and Arthritis Self-Management magazines regularly and blogs at www.diabetesselfmanagement.com/blog. See more of David’s work at www.davidsperorn.com.
That is the goal of Imcyse, a French company running a clinical trial with an immunotherapy designed to stop type 1 diabetes. Patients that have been diagnosed within the last 6 months, who still retain some insulin-producing cells, are given a treatment designed to make the immune system destroy the specific immune cells that are attacking insulin-producing cells. Results are expected later this year and will reveal whether the treatment has the potential to become a cure.
With a smaller food supply and a large influx of worthless and acidic mycotoxins, the organs become weak. When the organs become weak the immune system also becomes weak. And that is the missing link to why the immune system is weak. It is microbes and parasites in the organs which are starting the chain reaction of events that cause type 2 diabetes. The immune system may be attacking its own cells because the immune system has been weakened by microbes and parasites in the organs or the damage may be done by microbes and parasites attacking the organs directly.
The relationship between type 2 diabetes and the main modifiable risk factors (excess weight, unhealthy diet, physical inactivity and tobacco use) is similar in all regions of the world. There is growing evidence that the underlying determinants of diabetes are a reflection of the major forces driving social, economic and cultural change: globalization, urbanization, population aging, and the general health policy environment.
The blood vessels and blood are the highways that transport sugar from where it is either taken in (the stomach) or manufactured (in the liver) to the cells where it is used (muscles) or where it is stored (fat). Sugar cannot go into the cells by itself. The pancreas releases insulin into the blood, which serves as the helper, or the "key," that lets sugar into the cells for use as energy.
Regarding age, data shows that for each decade after 40 years of age regardless of weight there is an increase in incidence of diabetes. The prevalence of diabetes in persons 65 years of age and older is around 25%. Type 2 diabetes is also more common in certain ethnic groups. Compared with a 7% prevalence in non-Hispanic Caucasians, the prevalence in Asian Americans is estimated to be 8.0%, in Hispanics 13%, in blacks around 12.3%, and in certain Native American communities 20% to 50%. Finally, diabetes occurs much more frequently in women with a prior history of diabetes that develops during pregnancy (gestational diabetes).
In type I diabetes, insufficient levels of insulin result from the immune system itself attacking the pancreatic beta cells. On the other hand, while beta cell dysfunction varies widely between type II diabetes patients, insulin resistance is a major part of the disease. Restoring the beta cells of the pancreas to health is the treatment approach these two diseases share to some degree.
This makes Darkes' story seem less plausible, said Dr. Matthias von Herrath, a professor of developmental immunology at La Jolla Institute in California, and an expert in type 1 diabetes. This type of claim is "earth-shattering," he said. "If it's not well corroborated, it's like your grandmother's rumor kitchen" — there's nothing backing the story. If there is a clinical record and the data are clear, the doctors should publish a case report, Von Herrath told Live Science.
No matter the size of your organization—a WELCOA membership provides you with training and tools you need to change organizational culture, increase engagement, contain costs, and improve the lives of your employees. Ideal for workplace wellness and human resource professionals, benefits consultants and brokers—our solution encourages organizations to fuse knowledge and engage all team members to design your own highly personalized approach.
“I am extremely pleased to see that technology developed in Tejal Desai’s group is getting to the point that we can explore this for therapeutic purposes,” Matthias Hebrok, PhD, the director of the Diabetes Center at UCSF and a member of Encellin’s scientific advisory board, noted on the UCSF website. “Encapsulation and protection of islet cells remain a critical hurdle that needs to be overcome before cell therapy becomes a reality in type 1 diabetes.”
Encellin’s ultra thin-film device won a $10,000 research prize in The American Diabetes Association's 22nd Annual Leaders Forum HealthTech Showcase in Northern California in late 2017. The company also won a 2016 Innovation Award from the San Francisco-based Rosenman Institute, an organization that aims to support the development of innovative medical-device technologies.
Founded in 2006, Massachusetts-based biotechnology startup Gelesis has raised a total of $118.2 million for developing an oral smart pill. In 2016, the company initially filed an IPO offering of $60 million, but pulled out and instead focused on raising more funding. The technology is based on capsules filled with tiny hydrogel particles that expand between 50 to 100 times their weight in size after absorbing water from the stomach, which results in increased satiety to help obese diabetes patients lose weight and control their sugar metabolism. They are currently undergoing a phase 2 clinical trial on their Gelesis200 product for treating diabetes.
As a global network of medical research charities, the Juvenile Diabetes Research Foundation (JDRF) is driving research into new treatments that present tremendous opportunities to deliver enhanced health and wellbeing for people with type-1 diabetes. The technology I am currently most enthused about is glucose responsive insulin, which I think is going to transform how people treat and live with type 1 in the future.
Several types of plants are referred to as ginseng, but most studies have used American ginseng. They've shown some sugar-lowering effects in fasting and after-meal blood sugar levels, as well as in A1c results (average blood sugar levels over a 3-month period). But we need larger and more long-term studies. Researchers also found that the amount of sugar-lowering compound in ginseng plants varies widely.
When 69-year-old Sandi, of Houston, was diagnosed with type 2 diabetes in 2007, she was confident she’d be able to manage the disease well. “I felt like, ‘I have this handled, it will be great,’” she recalls. Yet after the death of her best friend, five years ago, she started to experience anxiety and depression, and, she says, “it started manifesting more with my diabetes.”
Low blood pressure on standing (orthostatic hypotension). Treatment starts with simple lifestyle changes, such as avoiding alcohol, drinking plenty of water, and sitting or standing slowly. Sleeping with the head of the bed raised 6 to 10 inches helps prevent swings in blood pressure. Your doctor may also recommend compression stockings and similar compression support for your abdomen (abdominal binder). Several medications, either alone or together, may be used to treat orthostatic hypotension.
Wellness was so unfamiliar at the time, Travis recalls, that he constantly had to spell the word when using it over the phone. It soon got national attention when a young doctoral student named Donald B. Ardell profiled Travis’s center in the April 1976 issue of Prevention magazine. In a sidebar, Prevention’s editor, Robert Rodale, welcomed the “exciting field of wellness enhancement,” promising that the magazine would “examine all aspects of wellness promotion.” Even greater exposure came with Rather’s “60 Minutes” piece, which focused on Travis and the Mill Valley center.
There is no known preventive measure for type 1 diabetes. Type 2 diabetes – which accounts for 85–90% of all cases – can often be prevented or delayed by maintaining a normal body weight, engaging in physical activity, and consuming a healthy diet. Higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%. Dietary changes known to be effective in helping to prevent diabetes include maintaining a diet rich in whole grains and fiber, and choosing good fats, such as the polyunsaturated fats found in nuts, vegetable oils, and fish. Limiting sugary beverages and eating less red meat and other sources of saturated fat can also help prevent diabetes. Tobacco smoking is also associated with an increased risk of diabetes and its complications, so smoking cessation can be an important preventive measure as well.
"Brittle" diabetes, also known as unstable diabetes or labile diabetes, is a term that was traditionally used to describe the dramatic and recurrent swings in glucose levels, often occurring for no apparent reason in insulin-dependent diabetes. This term, however, has no biologic basis and should not be used. Still, type 1 diabetes can be accompanied by irregular and unpredictable high blood sugar levels, frequently with ketosis, and sometimes with serious low blood sugar levels. Other complications include an impaired counterregulatory response to low blood sugar, infection, gastroparesis (which leads to erratic absorption of dietary carbohydrates), and endocrinopathies (e.g., Addison's disease). These phenomena are believed to occur no more frequently than in 1% to 2% of persons with type 1 diabetes.
The advice above is therefore not only illogical, but also works poorly. It completely lacks scientific support according to a Swedish expert investigation. On the contrary, in recent years similar carbohydrate-rich dietary advice has been shown to increase the risk of getting diabetes and worsen blood sugar levels long-term in people who are already diabetic. The advice doesn’t improve diabetics’ health in any other way either.
Founded in 1999, San Diego-based ViaCyte has raised a total of $201.5 million in funding, with major investments from Johnson & Johnson and Bain Capital. ViaCyte is addressing diabetes by developing a technology based on converting stem cells into pancreatic tissue that can produce insulin, and implanting the new tissue into patients inside an immunoprotective device for continuous insulin production.
The fact these improvements can happen independently of weight loss should also signify a shift in how we conceptualize both obesity and diabetes, according to Peter Billings, the Seattle bariatric surgeon who operated on Benari. Billings, a nearly 20-year veteran in the field, has started to perform surgery on other lower-BMI patients similar to Benari, though they often pay out of pocket.
^ Ahlqvist, Emma; Storm, Petter; Käräjämäki, Annemari; Martinell, Mats; Dorkhan, Mozhgan; Carlsson, Annelie; Vikman, Petter; Prasad, Rashmi B; Aly, Dina Mansour (2018). "Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables". The Lancet Diabetes & Endocrinology. 0 (5): 361–369. doi:10.1016/S2213-8587(18)30051-2. ISSN 2213-8587. PMID 29503172.
Insulin is a hormone that is produced by specialized cells (beta cells) of the pancreas. (The pancreas is a deep-seated organ in the abdomen located behind the stomach.) In addition to helping glucose enter the cells, insulin is also important in tightly regulating the level of glucose in the blood. After a meal, the blood glucose level rises. In response to the increased glucose level, the pancreas normally releases more insulin into the bloodstream to help glucose enter the cells and lower blood glucose levels after a meal. When the blood glucose levels are lowered, the insulin release from the pancreas is turned down. It is important to note that even in the fasting state there is a low steady release of insulin than fluctuates a bit and helps to maintain a steady blood sugar level during fasting. In normal individuals, such a regulatory system helps to keep blood glucose levels in a tightly controlled range. As outlined above, in patients with diabetes, the insulin is either absent, relatively insufficient for the body's needs, or not used properly by the body. All of these factors cause elevated levels of blood glucose (hyperglycemia).
Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes.